EGFR and non-small cell lung carcinoma: With a good tolerance, significantly improved PFS and OS were observed in the ABCP group compared with the BCP group for metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status.